Duchenne MD dad piv­ots from last-minute alert on FDA's par­tial hold to $125M IPO for Sol­id Bio

In most IPOs, risk fac­tors can range from any­thing from “our lead drug may not work” to the threat of famine and plague — they’re in­tend­ed to cov­er vir­tu­al­ly every con­tin­gency.

But as Ilan Gan­ot was out drum­ming up sup­port for his $125 mil­lion IPO for Sol­id Bio­sciences in re­cent months, there was one key risk fac­tor that hadn’t been in­clud­ed. The FDA had put its lead drug on par­tial clin­i­cal hold in No­vem­ber, with reg­u­la­tors re­fus­ing to al­low re­searchers to start test­ing the high dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER